Literature DB >> 30796689

A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience.

Claudio Ricci1, Davide Campana1, Chiara Casadei1, Carlo Ingaldi1, Valentina Ambrosini2, Nico Pagano1, Donatella Santini2, Cristina Mosconi2, Nicole Brighi2, Laura Alberici1, Francesco Minni1, Riccardo Casadei3.   

Abstract

PURPOSE: The primary end-point was to evaluate the cure fraction. Secondary end-points were to investigate the time to cure, the excess of death risk, the probability of cure and the factors related to these parameters.
METHODS: Retrospective study of an ENETS database regarding patients affected by Si-NENs. For each patients, clinical, pathological and follow-up data were collected. The survival analysis was made using a novel approach: the cure model approach.
RESULTS: The cure fraction was 92.1%. The death risk, time to cure and the probability of cure were 6/1000 person-years, 3.6 years and 98.2%, respectively. The independent factors influencing these parameters were the grading and the R status (P = 0.041 and P = 0.017, respectively). Patients affected by Si-NENs G2 increased the death risk and time to cure respect to Si-NENs G1 (51 versus 6 per 1000 person-years and 5.1 versus 3.6 years, respectively) as well as patients not operated respect to those radically resected (R0/1) (66 versus 1 per 1000 person-years and 4.8 versus 0.4 years, respectively). The probability of cure decreased (88.1 versus 97.8% and 80.4 versus 99.7%, respectively). R2 resection shows better results than no resection.
CONCLUSIONS: A large portion of patients affected by Si-NENs can be cured. The highest probability of cure regards patients with Si-NENs G1 who underwent to R0/R1 resection; the lower, those with Si-NENs G2 and no resection. R2 resection seems to be preferred respect to no resection.

Entities:  

Keywords:  Cure model; Neuroendocrine neoplasms; Small intestine

Mesh:

Year:  2019        PMID: 30796689     DOI: 10.1007/s12020-019-01870-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  13 in total

1.  ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum.

Authors:  B Niederle; U-F Pape; F Costa; D Gross; F Kelestimur; U Knigge; K Öberg; M Pavel; A Perren; C Toumpanakis; J O'Connor; D O'Toole; E Krenning; N Reed; R Kianmanesh
Journal:  Neuroendocrinology       Date:  2016-01-12       Impact factor: 4.914

2.  Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.

Authors:  Eugene A Woltering; Brianne A Voros; David T Beyer; Yi-Zarn Wang; Ramcharan Thiagarajan; Pamela Ryan; Anne Wright; Robert A Ramirez; M Jennifer Ricks; J Philip Boudreaux
Journal:  J Am Coll Surg       Date:  2017-01-11       Impact factor: 6.113

Review 3.  Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases.

Authors:  G Capurso; M Rinzivillo; R Bettini; L Boninsegna; G Delle Fave; M Falconi
Journal:  Br J Surg       Date:  2012-09-13       Impact factor: 6.939

4.  Endocrine tumors of the ileum: factors correlated with survival.

Authors:  Paola Tomassetti; Davide Campana; Lydia Piscitelli; Riccardo Casadei; Francesca Nori; Emilio Brocchi; Donatella Santini; Raffaele Pezzilli; Roberto Corinaldesi
Journal:  Neuroendocrinology       Date:  2006-10-02       Impact factor: 4.914

5.  Proportion cured models applied to 23 cancer sites in Norway.

Authors:  Milada Cvancarova; Bjarte Aagnes; Sophie D Fosså; Paul C Lambert; Bjørn Møller; Freddie Bray
Journal:  Int J Cancer       Date:  2012-12-14       Impact factor: 7.396

6.  Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis.

Authors:  Claudio Ricci; Riccardo Casadei; Giovanni Taffurelli; Davide Campana; Valentina Ambrosini; Carlo Alberto Pacilio; Donatella Santini; Nicole Brighi; Francesco Minni
Journal:  Pancreatology       Date:  2018-02-21       Impact factor: 3.996

7.  A 5-decade analysis of 13,715 carcinoid tumors.

Authors:  Irvin M Modlin; Kevin D Lye; Mark Kidd
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

8.  Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?

Authors:  Lan Huang; Kathleen A Cronin; Karen A Johnson; Angela B Mariotto; Eric J Feuer
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

9.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

10.  Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study.

Authors:  Lunpo Wu; Jianfei Fu; Li Wan; Jie Pan; Sanchuan Lai; Jing Zhong; Daniel C Chung; Liangjing Wang
Journal:  Oncotarget       Date:  2017-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.